Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Stage 2 Diastolic Hypertension Clear all

Completed Phase 4 Interventional Results available

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

NCT01218100

View directory record Official record

Conditions: Stage 2 Diastolic Hypertension
Interventions: nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 64 Years

Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 89
States / cities: Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more

Source: ClinicalTrials.gov public record

Updated Jun 20, 2012 · Synced May 21, 2026, 9:41 PM EDT

Terminated Phase 3 Interventional

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

NCT00376181

View directory record Official record

Conditions: Type 2 Diabetes
Interventions: Pioglitazone and Azilsartan, Pioglitazone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older

Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 59
States / cities: Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more

Source: ClinicalTrials.gov public record

Updated Jun 21, 2010 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394

View directory record Official record

Conditions: Hypertension
Interventions: Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 5, 2012 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 4 Interventional Results available

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

NCT00853957

View directory record Official record

Conditions: Hypertension
Interventions: Aliskiren/Amlodipine, Amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 9
States / cities: Chicago, Illinois • Baltimore, Maryland • Oxon Hill, Maryland + 6 more

Source: ClinicalTrials.gov public record

Updated Apr 29, 2012 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 4 Interventional Results available

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

NCT00797316

View directory record Official record

Conditions: Hypertension
Interventions: Aliskiren, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Source: ClinicalTrials.gov public record

Updated Mar 10, 2011 · Synced May 21, 2026, 9:41 PM EDT

Withdrawn Phase 2 Interventional

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

NCT07221513

View directory record Official record

Conditions: HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
Interventions: JK07; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Source: ClinicalTrials.gov public record

Updated May 14, 2026 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 4 Interventional Results available

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

NCT00942994

View directory record Official record

Conditions: Hypertension
Interventions: Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more

Source: ClinicalTrials.gov public record

Updated Jun 7, 2011 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 4 Interventional Results available

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

NCT00787605

View directory record Official record

Conditions: Hypertension, Diabetes Mellitus
Interventions: Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: East Hanover, New Jersey

Source: ClinicalTrials.gov public record

Updated Oct 26, 2016 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 3 Interventional

Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension

NCT00353912

View directory record Official record

Conditions: Hypertension
Interventions: valsartan + amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 571 participants
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Source: ClinicalTrials.gov public record

Updated Nov 17, 2016 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

NCT00739596

View directory record Official record

Conditions: Hypertension
Interventions: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Source: ClinicalTrials.gov public record

Updated Oct 26, 2016 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 3 Interventional

Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension

NCT00350168

View directory record Official record

Conditions: Hypertension
Interventions: valsartan + amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 647 participants
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Source: ClinicalTrials.gov public record

Updated Nov 17, 2016 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 4 Interventional Results available

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

NCT00772577

View directory record Official record

Conditions: Hypertension
Interventions: Aliskiren Hydrochlorothiazide, Ramipril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more

Source: ClinicalTrials.gov public record

Updated Mar 10, 2011 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 2 Interventional Results available

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

NCT00362115

View directory record Official record

Conditions: Hypertension
Interventions: Azilsartan Medoxomil, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older

Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 46
States / cities: Huntsville, Alabama • Ozark, Alabama • Mesa, Arizona + 43 more

Source: ClinicalTrials.gov public record

Updated Apr 18, 2011 · Synced May 21, 2026, 9:41 PM EDT

Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population

NCT00760266

View directory record Official record

Conditions: Hypertension
Interventions: Aliskiren, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older

Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Source: ClinicalTrials.gov public record

Updated Apr 3, 2011 · Synced May 21, 2026, 9:41 PM EDT